Analyst Price Targets — NRXS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 22, 2025 2:28 pm | — | Craig-Hallum | $8.00 | $3.39 | TheFly | Neuraxis price target raised to $8 from $7 at Craig-Hallum |
| June 16, 2025 11:28 am | Chase Knickerbocker | Craig-Hallum | $7.00 | $2.52 | TheFly | Neuraxis initiated with a Buy at Craig-Hallum |
Latest News for NRXS
CARMEL, Ind., April 10, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that on April 10, 2026, its Board of Directors declared a dividend on its Series B Preferred Stock.
NRXS witnesses strong revenue growth and expanding coverage in fourth-quarter 2025, but rising costs and commercialization investments weigh on profitability.
NeurAxis, Inc. (NRXS) Q4 2025 Earnings Call Transcript
CARMEL, Ind., March 19, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter period and full year ended December 31, 2025.
NeurAxis, Inc. (NASDAQ: NRXS - Get Free Report) fell 5.7% during trading on Thursday. The company traded as low as $4.54 and last traded at $4.63. 136,167 shares changed hands during mid-day trading, an increase of 4% from the average session volume of 130,490 shares. The stock had previously closed at $4.91. Analyst Upgrades and
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NRXS.
U.S. House Trading
No House trades found for NRXS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.